Centessa is a clinical-stage pharmaceutical company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients.
Centessa aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations.
Centessa was founded in 2020 by Medicxi. The company is headquartered in Cambridge, MA and London, UK.
Centessa applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry leading teams. Each program is developed by an Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.
Centessa's programs range from discovery-stage to late-stage development and include diverse therapeutic areas including oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology.
Centessa raised $250M in an oversubscribed Series A financing on Feb 16, 2021. The round was led by General Atlantic and co-led by Vida Ventures and Janus Henderson Investors. Other investors include Boxer Capital, Cormorant Asset Management, T. Rowe Price Associates, Venrock Healthcare, among many also participated in the round.